News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Nov 22, 2017
- 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017 - - Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on November 30, 2017 -
Nov 21, 2017
- Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program -
Oct 30, 2017
London, UK and Carlsbad, CA, 30 Oct 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S.
Sep 05, 2017
- Morgan Stanley 15th Annual Healthcare Conference on 13 September – - Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on 27 September-
Aug 07, 2017
- Epidiolex® NDA submission process underway – - Conference call today at 4:30 p.m. EST -
Jul 24, 2017
London, UK,  24 July 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2017 its th
Jun 07, 2017
London, UK, 7 June 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that GW management will
May 24, 2017
– Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control –
May 15, 2017
- Dr. Volker Knappertz appointed Chief Medical Officer - - Professor Ben Whalley to join as Head of Discovery Research -
May 09, 2017
- Epidiolex® NDA submission expected mid-year– - New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology -

Pages